These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 20068088)

  • 21. Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells.
    Bu Y; Yang Z; Li Q; Song F
    Oncology; 2008; 74(3-4):198-206. PubMed ID: 18714168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells.
    Spänkuch-Schmitt B; Wolf G; Solbach C; Loibl S; Knecht R; Stegmüller M; von Minckwitz G; Kaufmann M; Strebhardt K
    Oncogene; 2002 May; 21(20):3162-71. PubMed ID: 12082631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children.
    Triscott J; Lee C; Foster C; Manoranjan B; Pambid MR; Berns R; Fotovati A; Venugopal C; O'Halloran K; Narendran A; Hawkins C; Ramaswamy V; Bouffet E; Taylor MD; Singhal A; Hukin J; Rassekh R; Yip S; Northcott P; Singh SK; Dunham C; Dunn SE
    Cancer Res; 2013 Nov; 73(22):6734-44. PubMed ID: 24019381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of Polo-like Kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia.
    Didier C; Cavelier C; Quaranta M; Demur C; Ducommun B
    Eur J Pharmacol; 2008 Sep; 591(1-3):102-5. PubMed ID: 18616938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.
    Johnson EF; Stewart KD; Woods KW; Giranda VL; Luo Y
    Biochemistry; 2007 Aug; 46(33):9551-63. PubMed ID: 17655330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells.
    Grinshtein N; Datti A; Fujitani M; Uehling D; Prakesch M; Isaac M; Irwin MS; Wrana JL; Al-Awar R; Kaplan DR
    Cancer Res; 2011 Feb; 71(4):1385-95. PubMed ID: 21303981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors.
    Beria I; Ballinari D; Bertrand JA; Borghi D; Bossi RT; Brasca MG; Cappella P; Caruso M; Ceccarelli W; Ciavolella A; Cristiani C; Croci V; De Ponti A; Fachin G; Ferguson RD; Lansen J; Moll JK; Pesenti E; Posteri H; Perego R; Rocchetti M; Storici P; Volpi D; Valsasina B
    J Med Chem; 2010 May; 53(9):3532-51. PubMed ID: 20397705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-mitotic functions of polo-like kinases in cancer cells.
    Raab CA; Raab M; Becker S; Strebhardt K
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188467. PubMed ID: 33171265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.
    Mross K; Frost A; Steinbild S; Hedbom S; Rentschler J; Kaiser R; Rouyrre N; Trommeshauser D; Hoesl CE; Munzert G
    J Clin Oncol; 2008 Dec; 26(34):5511-7. PubMed ID: 18955456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polo-like kinase (Plk) 1 as a target for prostate cancer management.
    Reagan-Shaw S; Ahmad N
    IUBMB Life; 2005 Oct; 57(10):677-82. PubMed ID: 16223707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma.
    Nappi TC; Salerno P; Zitzelsberger H; Carlomagno F; Salvatore G; Santoro M
    Cancer Res; 2009 Mar; 69(5):1916-23. PubMed ID: 19223553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid functional screening of effective siRNAs against Plk1 and its growth inhibitory effects in laryngeal carcinoma cells.
    Lan H; Zhu J; Ai Q; Yang Z; Ji Y; Hong S; Song F; Bu Y
    BMB Rep; 2010 Dec; 43(12):818-23. PubMed ID: 21189159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors.
    Hofheinz RD; Al-Batran SE; Hochhaus A; Jäger E; Reichardt VL; Fritsch H; Trommeshauser D; Munzert G
    Clin Cancer Res; 2010 Sep; 16(18):4666-74. PubMed ID: 20682708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma.
    Stewart HJ; Kishikova L; Powell FL; Wheatley SP; Chevassut TJ
    Exp Hematol; 2011 Mar; 39(3):330-8. PubMed ID: 21184800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1.
    Reindl W; Strebhardt K; Berg T
    Anal Biochem; 2008 Dec; 383(2):205-9. PubMed ID: 18793607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies.
    Ikezoe T; Yang J; Nishioka C; Takezaki Y; Tasaka T; Togitani K; Koeffler HP; Yokoyama A
    Leukemia; 2009 Sep; 23(9):1564-76. PubMed ID: 19421227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
    Nihal M; Stutz N; Schmit T; Ahmad N; Wood GS
    Cell Cycle; 2011 Apr; 10(8):1303-11. PubMed ID: 21436619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.
    Kreis NN; Louwen F; Zimmer B; Yuan J
    Oncotarget; 2015 Mar; 6(9):6611-26. PubMed ID: 25483104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells.
    de Oliveira JC; Brassesco MS; Pezuk JA; Morales AG; Valera ET; Montaldi AP; Sakamoto-Hojo ET; Scrideli CA; Tone LG
    J Drugs Dermatol; 2012 May; 11(5):587-92. PubMed ID: 22527426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.
    Lénárt P; Petronczki M; Steegmaier M; Di Fiore B; Lipp JJ; Hoffmann M; Rettig WJ; Kraut N; Peters JM
    Curr Biol; 2007 Feb; 17(4):304-15. PubMed ID: 17291761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.